bf/NASDAQ:TCRR_icon.jpeg

COM:TCR2

Adaptimmune

  • Stock

Last Close

1.48

31/05 20:00

Market Cap

58.11M

Beta: -

Volume Today

3.75M

Avg: -

  • locale

    usUnited States
  • market

    STOCKS
  • industry

    Biotechnology
  • website

    www.tcr2.com
  • ipo date

    Feb 14, 2019

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small ...Show More

competitor of